Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
Status:
Completed
Trial end date:
2021-05-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the
current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in
patients with mild-moderate COVID-19 disease.
Patients will attend 4 study visits over a period of up to 28 days.